FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.

@article{Ryan2008FDADA,
  title={FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.},
  author={Qin Ryan and Amna M. Ibrahim and Martin H. Cohen and John R. Johnson and Chia-wen Ko and Rajeshwari Sridhara and Robert Justice and Richard Pazdur},
  journal={The oncologist},
  year={2008},
  volume={13 10},
  pages={1114-9}
}
On March 13, 2007, the U.S. Food and Drug Administration approved lapatinib (Tykerb tablets; GlaxoSmithKline, Philadelphia), an oral, small molecule, dual tyrosine kinase inhibitor of ErbB-2 and ErbB-1, for use in combination with capecitabine for the treatment of patients with human epidermal growth factor receptor (HER)-2-overexpressing metastatic breast cancer who had received prior therapy including an anthracycline, a taxane, and trastuzumab. One multicenter, open-label, randomized trial… CONTINUE READING
71 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 71 extracted citations

Similar Papers

Loading similar papers…